The Price of Power in Pharma: AstraZeneca's Potential Megamerger A potential merger between pharmaceutical giants AstraZeneca and Bristol Myers Squibb has sent shockwaves through the industry, with estimates valuing the combined company at a staggering $400 billion.
This deal would create a behemoth with the resources to shape regulatory policy, dictate research agendas, and dominate the global market.
Both companies have built their empires through strategic acquisitions and innovative research. AstraZeneca's portfolio is impressive, with breakthroughs in oncology and respiratory medicine.